All lobbying filings

AKIN GUMP STRAUSS HAUER & FELD

Lobbying for CHATTEM, INC. DBA OPELLA · Manufacturer of consumer healthcare products.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $70,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 4

HR 4273
Over-the-Counter Monograph Drug User Fee Amendments
S 2292
Over-the-Counter Monograph Drug User Fee Amendments
S 2529
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription …
HR 5371
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …

Lobbying activity 2

Health Issues

Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.

Trade (domestic/foreign)

Issues related to imports of unavailable natural resources.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.